OVVI Diagnostics is a Belgium-based startup founded in 2020 in Liege, specializing in biotechnology and health care. The company is dedicated to developing the first Point-of-Care testing system exclusively focused on women’s health.
OVVI Diagnostics leverages the MIAtek® technology, a magnetic detection technology acquired from Magnisense, and collaborates with industry leaders in antibody generation and highly sensitive lateral flow technology. The startup aims to build a comprehensive Point-of-Care testing solution catering to women's health issues at different stages of their lives.
Their focus includes tests performed by OB/GYNs during consultations or in hospitals, as well as self-testing by patients or nurses at home, with results automatically transmitted to physicians.
The company's Headquarters are located at GIGA, the University of Liège’s interdisciplinary research institute in the biomedical sciences. Additionally, OVVI Diagnostics France SE, a subsidiary of Ovvi Diagnostics Srl, operates its R&D laboratories in Dardilly, Lyon and is a member of LyonBiopole, the regional cluster for the healthcare and life sciences sector.
As of now, details about the last investment and the investors involved are not publicly disclosed.